Cargando…

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

PURPOSE: Combining radiotherapy (RT) with DNA damage response inhibitors may lead to increased tumor cell death through radiosensitization. DNA-dependent protein kinase (DNA-PK) plays an important role in DNA double-strand break repair via the nonhomologous end joining (NHEJ) pathway. We hypothesize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Kyoko, Karmokar, Ankur, Farrington, Paul M., James, Neil H., Ramos-Montoya, Antonio, Bickerton, Susan J., Hughes, Gareth D., Illidge, Timothy M., Cadogan, Elaine B., Davies, Barry R., Dovedi, Simon J., Valge-Archer, Viia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401489/ https://www.ncbi.nlm.nih.gov/pubmed/34011558 http://dx.doi.org/10.1158/1078-0432.CCR-20-3701

Ejemplares similares

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
por: Fok, Jacqueline H. L., et al.
Publicado: (2019)

AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
por: Lapa, Beatriz Santos, et al.
Publicado: (2023)

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
por: Tew, Ben Yi, et al.
Publicado: (2023)

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments
por: Sitnikova, Suzanne I., et al.
Publicado: (2023)

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
por: Illuzzi, Giuditta, et al.
Publicado: (2022)

A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
por: Ding, Nan, et al.
Publicado: (2023)

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation
por: Lopez-Pelaez, Marta, et al.
Publicado: (2022)

A cell-engineered system to assess tumor cell sensitivity to CD8(+) T cell-mediated cytotoxicity
por: Nelson, Nadine, et al.
Publicado: (2019)

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
por: Vesely, Clare, et al.
Publicado: (2022)

Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
por: van IJzendoorn, David G.P., et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
por: Lozano-Rabella, Maria, et al.
Publicado: (2023)

Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
por: Rastegar, Bahar, et al.
Publicado: (2023)

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
por: Sivakumar, Smruthy, et al.
Publicado: (2023)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
por: Rodriguez-Berriguete, Gonzalo, et al.
Publicado: (2023)

Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors
por: Srinivasan, Ethan S., et al.
Publicado: (2023)

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
por: Leng, Dongliang, et al.
Publicado: (2023)

Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
por: Nash, Amanda M., et al.
Publicado: (2022)

Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
por: Soni, Upendra Kumar, et al.
Publicado: (2023)

MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Borcherding, Dana C., et al.
Publicado: (2023)

Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
por: Derry, Jonathan M.J., et al.
Publicado: (2023)

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
por: Stokes, Michael E., et al.
Publicado: (2023)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1(+) Macrophages and Fibroblasts
por: Sathe, Anuja, et al.
Publicado: (2023)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
por: Fernández-Miranda, Ismael, et al.
Publicado: (2023)

A Novel B7-H6–Targeted IgG-Like T Cell–Engaging Antibody for the Treatment of Gastrointestinal Tumors
por: Zhang, Wei, et al.
Publicado: (2022)

Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
por: Hanna, Glenn J., et al.
Publicado: (2023)

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
por: Su, Yudong, et al.
Publicado: (2022)

Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors
por: Yavropoulou, Maria P, et al.
Publicado: (2015)

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
por: Jogo, Tomoko, et al.
Publicado: (2021)

Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma
por: Berger, Barry M., et al.
Publicado: (2022)

Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
por: Nathenson, Michael J., et al.
Publicado: (2022)

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
por: Febres-Aldana, Christopher A., et al.
Publicado: (2022)

A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2023)

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
por: Bessede, Alban, et al.
Publicado: (2023)

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
por: Peper-Gabriel, Janet K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ofvl5o4cnhaudlas81pell9p0